Skip to main content

Table 1 Baseline characteristics of study population (N = 376)

From: Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study

Maternal characteristic

n (%)

Age

  ≤ 20 years

10 (2.7)

  > 20 to 30 years

181 (48.1)

  > 30 to 40 years

178 (47.3)

  > 40 to 50 years

7 (1.9)

Obstetric history

  ≥ 1 prior pregnancy

221 (58.8)

 1 prior pregnancy resulting in fetal stillbirth (≥ 22 weeks)

2 (0.5)

 1 prior miscarriage

53 (14.1)

 2 prior miscarriages

11 (2.9)

 3 prior miscarriages

4 (1.1)

 4 prior miscarriages

1 (0.3)

  > 4 prior miscarriages

2 (0.5)

  > 4 prior pregnancies resulting in fetal stillbirth (≥ 22 weeks)

1 (0.3)

 1 prior elective/therapeutic abortion

28 (7.4)

 2 prior elective/therapeutic abortions

4 (1.1)

 1 prior ectopic pregnancy

3 (0.8)

Concomitant medications

 Prenatal vitamins

168 (44.7)

 Baclofen

29 (7.7)

 Folic acid

22 (5.9)

 Modafinil

21 (5.6)

 Multivitamins

19 (5.1)

Prior medical history

 Chicken pox

294 (78.2)

 Urinary tract infection

135 (35.9)

 Abnormal Pap test

109 (29.0)

 Gynecological surgery

55 (14.6)

 Breathing disorder

46 (12.2)

 Sexually transmitted disease

39 (10.4)

 Breast cancer

1 (0.3)

 Cervical cancer

1 (0.3)

 Lymphoma

1 (0.3)

 Melanoma

1 (0.3)

Social risk factorsa

 Caffeine use

235 (62.5)

 Alcohol consumption

70 (18.6)

 Tobacco use

59 (15.7)

 Illicit drug use

7 (1.2)

  1. aOf patients who reported caffeine, alcohol, tobacco, or illicit drug use at enrollment, 168 of 235 (71.5 %), 7 of 70 (10.0 %), 25 of 59 (42.4 %), and 1 of 7 (14.3 %), respectively, continued use during pregnancy